{"created":"2023-07-27T06:29:43.322930+00:00","id":14488,"links":{},"metadata":{"_buckets":{"deposit":"c9ac7f9e-1469-4bc1-b86a-27eb0f87693b"},"_deposit":{"created_by":3,"id":"14488","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14488"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014488","sets":["1132:1133:1134"]},"author_link":["842","861","20454","1223","1231"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-02-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"166","bibliographicPageStart":"155","bibliographicVolumeNumber":"23","bibliographic_titles":[{"bibliographic_title":"泌尿器外科 = Japanese journal of urological surgery"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"「はじめに」<勝岡>2009年9月に, 国内で初めての前立腺肥大症に適応が認められた1, 2型5α還元酵素阻害薬, デュタステリド(商品名：アボルブ(R))0.5mgが発売されました. 本日は, デュタステリドの国内臨床試験の結果, 作用機序, それから海外臨床試験の結果, ならびに安全性と今後の課題などをテーマにご意見を伺いたいと思います. 「デュタステリド開発の経緯と国内臨床試験」<勝岡>最初に, 本剤の開発の経緯についてご紹介させていただきます. 海外においては1996年から第II相試験に着手し, 1997～2003年に第III相試験が実施されています. これらの試験結果により, 米国では2001年12月に前立腺肥大症の適応を取得し, その後2002年10月に尿閉あるいは手術へのリスクの減少という適応を追加しています. 一方, 欧州においては2002年7月に前述の適応を取得しています. また, 近年実施されたCombAT studyの成績に基づき, 欧米では2008年の4月あるいは6月にαブロッカーとの併用療法という適応を追加しています.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"医学図書出版"}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.igakutosho.co.jp/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 医学図書出版 | 許可を得て登録"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10064459","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0914-6180","subitem_source_identifier_type":"ISSN"}]},"item_4_text_2":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_text_value":"[泌尿器外科 誌上座談会]前立腺肥大症に対する5α還元酵素阻害薬の有用性について"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"勝岡, 洋治"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"塚本, 泰司"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"並木, 幹夫"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"後藤, 百万"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"高橋, 悟"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-NAMIKI-M-155.pdf","filesize":[{"value":"10.1 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-NAMIKI-M-155.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14488/files/ME-PR-NAMIKI-M-155.pdf"},"version_id":"111e6f3b-7911-4128-a34f-2bb5ae0ce65e"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"前立腺肥大症に対する5α還元酵素阻害薬の有用性について","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"前立腺肥大症に対する5α還元酵素阻害薬の有用性について"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14488","relation_version_is_last":true,"title":["前立腺肥大症に対する5α還元酵素阻害薬の有用性について"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:46:53.933675+00:00"}